Hospital
Fauquier Medical Center LLC
Fauquier Medical Center LLC was paid $12.86M by Medicaid between Jan 2018 and Dec 2024, across 160 billing codes. Its largest line is 99284, emergency room visit (serious) — 18% of everything it billed.
33Billing provider infoFAUQUIER MEDICAL CENTER LLC
WARRENTON, VA 20186
WARRENTON, VA 20186
33aNPI1912334517assigned 09/27/2013
33bProvider typeGeneral Acute Care Hospital
28Total paid$12.86M
24GClaims323,859
24DCodes billed160
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#44 of 80
Median peer was paid$14.69M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 49,211 | $1.37M | |
| 2019 | 59,366 | $2.05M | |
| 2020 | 44,332 | $1.74M | |
| 2021 | 46,908 | $1.74M | |
| 2022 | 46,540 | $2.01M | |
| 2023 | 48,722 | $2.25M | |
| 2024incomplete | 28,780 | $1.70M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 13,894 | 11,405 | $2.31M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 12,425 | 10,859 | $2.18M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.5% | 6,094 | 5,005 | $836K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 5.3% | 3,925 | 1,471 | $680K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5.1% | 12,704 | 3,816 | $660K |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.1% | 2,806 | 2,226 | $655K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 4.9% | 11,316 | 3,785 | $632K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 4.3% | 3,595 | 3,293 | $552K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.2% | 2,456 | 2,152 | $542K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.8% | 3,340 | 2,968 | $493K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.8% | 2,913 | 2,405 | $488K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 3.1% | 5,567 | 1,848 | $394K |
148 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.1% | 2,479 | $394K |
| G0378 | Hospital observation service, per hour | 1.7% | 1,700 | $223K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.5% | 2,344 | $197K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.4% | 816 | $175K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 723 | $116K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,958 | $87K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,008 | $83K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,475 | $75K |
| 59025 | Fetal non-stress test | <1% | 404 | $74K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,079 | $72K |
| 80053 | Comprehensive metabolic panel | <1% | 14,296 | $57K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,691 | $52K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 851 | $52K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 95 | $45K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 447 | $44K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,686 | $43K |
| G0237 | Therapeutic procedures to increase strength or endurance of respiratory muscles, face to face, one on one, each 15 minutes (includes monitoring) | <1% | 1,132 | $42K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 139 | $41K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 157 | $36K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 492 | $36K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,877 | $29K |
| 97113 | <1% | 456 | $27K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 7,969 | $26K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 146 | $24K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,136 | $24K |
| 97162 | <1% | 149 | $22K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 388 | $17K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,841 | $13K |
| 97116 | <1% | 449 | $13K | |
| 71045 | Radiologic examination, chest; single view | <1% | 6,736 | $12K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 46 | $12K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 662 | $11K |
| 83735 | <1% | 4,920 | $10K | |
| 85027 | <1% | 15,992 | $10K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,721 | $10K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,439 | $10K |
| 80061 | Lipid panel | <1% | 1,414 | $9K |
| G0238 | Therapeutic procedures to improve respiratory function, other than described by g0237, one on one, face to face, per 15 minutes (includes monitoring) | <1% | 1,003 | $9K |
| J3490 | Unclassified drugs | <1% | 4,110 | $9K |
| 81001 | <1% | 10,930 | $9K | |
| 76830 | Ultrasound, transvaginal | <1% | 68 | $8K |
| 74018 | <1% | 306 | $8K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,843 | $8K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 16 | $8K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 7,637 | $8K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 60 | $7K |
| 73630 | <1% | 491 | $6K | |
| 84484 | <1% | 5,083 | $6K | |
| 84703 | <1% | 5,286 | $6K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,014 | $5K |
| 93971 | <1% | 47 | $5K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,152 | $5K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,554 | $5K |
| 73610 | <1% | 448 | $5K | |
| 93000 | <1% | 2,308 | $5K | |
| 73030 | <1% | 328 | $5K | |
| 87040 | <1% | 749 | $4K | |
| 85379 | <1% | 925 | $4K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,702 | $4K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 66 | $4K |
| 83880 | <1% | 488 | $3K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 475 | $3K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,709 | $3K |
| 76642 | <1% | 28 | $3K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 12 | $3K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,306 | $2K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 2,427 | $2K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 443 | $2K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 14 | $2K |
| 76770 | <1% | 18 | $2K | |
| 82962 | <1% | 5,998 | $2K | |
| 88342 | <1% | 211 | $2K | |
| 97010 | <1% | 105 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 116 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,668 | $2K |
| 80076 | <1% | 568 | $2K | |
| J1815 | Injection, insulin, per 5 units | <1% | 95 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,203 | $2K |
| 87070 | <1% | 2,577 | $2K | |
| 85610 | <1% | 3,755 | $2K | |
| 73564 | <1% | 119 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 839 | $1K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 31 | $1K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 15 | $1K |
| 83605 | <1% | 1,030 | $1K | |
| 73110 | <1% | 54 | $1K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 13 | $1K |
| 87186 | <1% | 1,656 | $1K | |
| 73130 | <1% | 64 | $1K | |
| 87400 | <1% | 193 | $1K | |
| 85730 | <1% | 2,725 | $968.00 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,050 | $891.19 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 66 | $707.23 |
| 92523 | <1% | 13 | $611.84 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,349 | $590.07 |
| 87077 | <1% | 1,074 | $583.55 | |
| 86850 | <1% | 382 | $566.89 | |
| 86900 | <1% | 835 | $526.05 | |
| 82607 | <1% | 96 | $523.99 | |
| 86901 | <1% | 836 | $455.80 | |
| 72110 | <1% | 13 | $449.12 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,816 | $393.67 |
| 83690 | <1% | 5,698 | $386.14 | |
| 84439 | <1% | 62 | $359.34 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,603 | $334.65 |
| 90715 | <1% | 12 | $254.50 | |
| 82746 | <1% | 43 | $226.58 | |
| 87205 | <1% | 655 | $197.69 | |
| 96376 | <1% | 2,091 | $161.67 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,642 | $142.54 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 338 | $132.24 |
| 84100 | <1% | 482 | $128.33 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,429 | $104.27 |
| 97168 | <1% | 17 | $104.27 | |
| 86140 | <1% | 101 | $102.18 | |
| 97164 | <1% | 22 | $98.74 | |
| 82728 | <1% | 13 | $94.47 | |
| 85652 | <1% | 130 | $93.25 | |
| 84702 | <1% | 103 | $92.17 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,115 | $76.64 |
| J2704 | Injection, propofol, 10 mg | <1% | 3,101 | $70.67 |
| 97597 | <1% | 25 | $68.38 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 792 | $63.75 |
| 87147 | <1% | 217 | $34.17 | |
| 82803 | <1% | 137 | $25.90 | |
| 87088 | <1% | 53 | $18.99 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 544 | $17.85 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 94 | $12.44 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 81 | $5.91 |
| 82043 | <1% | 15 | $5.15 | |
| 82550 | <1% | 15 | $2.91 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 16 | $2.23 |
| A9270 | Non-covered item or service | <1% | 5,552 | $0.40 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 126 | $0.00 |
| 36600 | 0% | 17 | $0.00 | |
| 88312 | 0% | 24 | $0.00 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 15 | $0.00 |
| 82375 | 0% | 17 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 76 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 19 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 20 | $0.00 |
| 99152 | 0% | 17 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 20 | $0.00 |
| C1769 | Guide wire | 0% | 101 | $0.00 |
| 87807 | 0% | 205 | $0.00 | |
| 88304 | 0% | 18 | $0.00 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 15 | $0.00 |
| 76801 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.